Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziwen Tan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biostatistics (Oxford, England)|March 24, 2016
Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcomeZiwen Tan, Guoyou Qin, Haibo Zhou
IEEE Transactions on Image Processing : a Publication of the IEEE Signal Processing Society|March 3, 2025
Omnidirectional Image Quality Captioning: A Large-Scale Database and a New ModelJiebin Yan, Ziwen Tan, Yuming Fang, et al.
The British Journal of Nutrition|July 10, 2014
Heterogeneous associations of insoluble dietary fibre intake with subsequent glycosylated Hb levels among Chinese adults with type 2 diabetes: a quantile regression approachZiwen Tan, Xiaonan Ruan, Yue Chen, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Blood Advances|October 12, 2021
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphomaHaiyan Yang, Bing Xiang, Yuqin Song, et al.
The FEBS Journal|December 13, 2023
Sequence differences between BAX and BAK core domains manifest as differences in their interactions with lipidsMichelle S Miller, Angus D Cowan, Jason M Brouwer, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
BMJ Open|February 16, 2022
Are cause of death data for Shanghai fit for purpose? A retrospective study of medical recordsLei Chen, Tian Xia, Zheng-An Yuan, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biostatistics (Oxford, England)|March 24, 2016
Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcomeZiwen Tan, Guoyou Qin, Haibo Zhou
IEEE Transactions on Image Processing : a Publication of the IEEE Signal Processing Society|March 3, 2025
Omnidirectional Image Quality Captioning: A Large-Scale Database and a New ModelJiebin Yan, Ziwen Tan, Yuming Fang, et al.
The British Journal of Nutrition|July 10, 2014
Heterogeneous associations of insoluble dietary fibre intake with subsequent glycosylated Hb levels among Chinese adults with type 2 diabetes: a quantile regression approachZiwen Tan, Xiaonan Ruan, Yue Chen, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Blood Advances|October 12, 2021
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphomaHaiyan Yang, Bing Xiang, Yuqin Song, et al.
The FEBS Journal|December 13, 2023
Sequence differences between BAX and BAK core domains manifest as differences in their interactions with lipidsMichelle S Miller, Angus D Cowan, Jason M Brouwer, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
BMJ Open|February 16, 2022
Are cause of death data for Shanghai fit for purpose? A retrospective study of medical recordsLei Chen, Tian Xia, Zheng-An Yuan, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Pageof 1